Guided Therapeutics (GTHP) FCF Margin (2011 - 2025)
Guided Therapeutics recorded quarterly FCF Margin of 49.32% in Q4 2025, up 89.32% quarter-over-quarter from 461.67% in Q3 2025, and up 3315068.0% year-over-year from N/an in Q4 2024.
Guided Therapeutics' FCF Margin history runs 15 years deep, the most recent figure standing at 49.32% for Q4 2025.
- In Q4 2025, FCF Margin rose 3315068.0% year-over-year to 49.32%; the TTM figure through Dec 2025 stood at 139.24% (up 1584647.0% YoY), while the FY2025 annual figure was 139.5%, up 1584621.0% from the prior year.
- FCF Margin came in at 49.32% for Q4 2025 at Guided Therapeutics, up from 461.67% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 258.33% in Q4 2021 to a low of 34800.0% in Q2 2021.
- A 5-year average of 7840.94% and a median of 1967.42% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin sank 3215000 bps in 2024 and soared 3315068 bps in 2025, its largest moves.
- Guided Therapeutics' FCF Margin stood at 258.33% in 2021, then tumbled by 7958 bps to 20300.0% in 2022, then surged by 95 bps to 1050.0% in 2023, then plunged by 3062 bps to 33200.0% in 2024, then surged by 100 bps to 49.32% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 49.32%, 461.67%, and 144.44% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 25.51% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -1.28% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.68% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 37.67% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 3.98% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.44% |
| 10 | Guided Therapeutics | - | - | 458,000.00 | -49.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49.32% |
| Sep 30, 2025 | -461.67% |
| Jun 30, 2025 | -144.44% |
| Dec 31, 2024 | -33,200.00% |
| Mar 31, 2024 | -1,666.67% |
| Dec 31, 2023 | -1,050.00% |
| Jun 30, 2023 | -995.45% |
| Mar 31, 2023 | -2,268.18% |
| Sep 30, 2022 | -20,300.00% |
| Jun 30, 2022 | -7,320.00% |
| Mar 31, 2022 | -3,860.00% |
| Dec 31, 2021 | 258.33% |
| Sep 30, 2021 | -3,915.79% |
| Jun 30, 2021 | -34,800.00% |
| Dec 31, 2020 | -1,324.00% |
| Sep 30, 2020 | -787.01% |
| Dec 31, 2019 | -1,275.00% |
| Sep 30, 2019 | -22,800.00% |
| Jun 30, 2019 | -18,800.00% |
| Mar 31, 2019 | -1,033.33% |
| Dec 31, 2018 | -740.48% |
| Sep 30, 2018 | -20,850.00% |
| Jun 30, 2018 | -3,025.00% |
| Mar 31, 2018 | -9,875.00% |
| Dec 31, 2017 | -619.63% |
| Sep 30, 2017 | -618.18% |
| Jun 30, 2017 | 149.43% |
| Mar 31, 2017 | -1,938.10% |
| Dec 31, 2016 | 40.53% |
| Dec 31, 2015 | -66.67% |
| Sep 30, 2015 | -25.00% |
| Sep 30, 2014 | -113.64% |
| Jun 30, 2014 | -1,045.45% |
| Mar 31, 2014 | -21.05% |
| Dec 31, 2013 | 63.01% |
| Sep 30, 2013 | -11.63% |
| Mar 31, 2013 | -60.48% |
| Dec 31, 2012 | 103.56% |
| Sep 30, 2012 | -20.92% |
| Jun 30, 2012 | -52.57% |
| Mar 31, 2012 | 18.11% |
| Dec 31, 2011 | 20.09% |
| Sep 30, 2011 | 22.43% |
| Jun 30, 2011 | 2.08% |
| Mar 31, 2011 | 2.09% |